HODGKIN’S LYMPHOMA THERAPY OF A FEMALE IN HOSPITAL OF ISLAMABAD, PAKISTAN; A CASE REPORT
Riphah Institute of Pharmaceutical Sciences, Riphah International University, G-7/4,7th Avenue, Islamabad, Pakistan.
Keywords: Hodgkin lymphoma, female, pharmaceutical care, clinical responsibilities.
Hodgkin’s lymphoma (HL) is most curable form of cancer. HL accounts for 10% of lymphoma. The etiology of it remains unrevealed for a long time, now the outlook for HL has improved over the past 30 years. It responds well to the treatment. The cure rate tends to be higher in adults as compare to the elder ones. A nineteen year female was presented in a hospital with HL. On basis of her medical investigation the physician prescribed intravenous decadron 8mg in normal saline of 500ml once, adriblastina 30 mg in normal saline 100ml over 10 mins, setrovel 5mg IV, bleomycin 15mg IV, vinblastin 6mg IV,DTIC 430 MG in 5% D/W 500 mg IV over 3 hours and filgen 300mg S.C once daily. Vital signs showed fever, weakness and loss of appetite.PR 118/minute, 100 F temperature, and BP 90 /60, Wt 37 kg. General appearance was paleness, fever and anemia. Lab tests: Hb 6, Platelets 82,000.TLC 55000, AFB +ve, MCV 73.4, MCH 21.1.There were certain inaccuracies seen during treatment. So an optimal and safe clinical practice should be implement in health centres.Poor and sub-standard services should be minimize to enhance and improve the health and pharmaceutical care. Thus; the proper clinical care should be delivered to minimize the health hazards related to this mortal disease.
© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made.
You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits